Loading…
We use essential cookies (authentication, your saved goals/stack) by default. With your permission we'll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Head-to-head evidence comparison — which supplement is right for you?
Iron wins 3 of 3 categories. Both are solid choices — the best pick depends on your specific goals.
Verdict
Likely helps
11 of 15 studies with measurable effects showed benefit.
Top outcomes
Verdict
Mostly mechanism / observational
Top outcomes
18-45mg elemental iron for deficiency (varies by severity)
On empty stomach if tolerated, Away from tea, coffee, dairy
Ferrous bisglycinate (gentle, well-absorbed) or iron protein succinylate
Once-weekly subcutaneous injection, started at 2.5 mg and escalated by 2.5 mg every 4 weeks to a maintenance dose of 5, 10, or 15 mg (per the prescribing physician and approved indication)
any
Once-weekly subcutaneous injection (Mounjaro / Zepbound)
2-4 weeks
4-8 weeks
4-12 weeks
Weeks to months
Months (dose-escalated over ~20 weeks)
Weeks to months
Mostly during titration
Daily oral iron supplementation during pregnancy
The Cochrane database of systematic reviews (2024) · Meta analysis · n=48971
There is probably little to no difference in maternal death (2 versus 4 events, RR 0.57, 95% CI 0.12 to 2.69; 3 trials, 14,060 women; moderate-certainty evidence).
The Prevalence of Anemia among Pregnant Women in China: A Systematic Review and Meta-Analysis
Nutrients (2024) · Meta analysis · n=722
The results showed that the prevalence of anemia, ID, and IDA among pregnant women in China were 30.7% (95% CI: 26.6%, 34.7%), 45.6% (95% CI: 37.0%, 54.2%), and 17.3% (95% CI: 13.9%, 20.7%), respectively.
Treatment for women with postpartum iron deficiency anaemia
The Cochrane database of systematic reviews (2024) · Meta analysis · n=572
Intravenous iron versus oral iron supplementation The evidence is very uncertain about the effect of intravenous iron on mortality (risk ratio (RR) 2.95, 95% confidence interval (CI) 0.12 to 71.96; P = 0.51; I² = not applicable; 3 RCTs; 1 event; 572 women; very low-certainty evidence).
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.
N Engl J Med (2021) · Rct · n=1879
Open-label 40-week phase-3 head-to-head RCT (SURPASS-2) in 1879 patients with type 2 diabetes, tirzepatide 5/10/15 mg vs semaglutide 1 mg
Tirzepatide Once Weekly for the Treatment of Obesity.
N Engl J Med (2022) · Rct · n=2539
72-week phase-3 double-blind RCT (SURMOUNT-1) in 2539 adults with obesity (without diabetes), tirzepatide 5/10/15 mg vs placebo
Tirzepatide as Compared with Semaglutide for the Treatment of Obesity.
N Engl J Med (2025) · Rct · n=751
Phase-3b open-label head-to-head RCT (SURMOUNT-5) in 751 adults with obesity but without diabetes, max-tolerated tirzepatide vs max-tolerated semaglutide
Based on meta-analyses showing hemoglobin improvements of 2.01-5.30 g/dL in iron deficient populations. Higher doses show diminishing returns with increased GI side effects. Effectiveness varies significantly by baseline iron status and form used.
AI-estimated from published studies. Interpret as directional guidance.
Iron has a higher evidence score (9/10 vs 7.8/10) and wins in 3 of 3 categories.
No known interactions between Iron and Tirzepatide have been documented in our database. However, always consult a healthcare provider before combining supplements.